<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pancreas-kidney transplantation in diabetes mellitus: Surgical considerations and immunosuppression</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pancreas-kidney transplantation in diabetes mellitus: Surgical considerations and immunosuppression</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pancreas-kidney transplantation in diabetes mellitus: Surgical considerations and immunosuppression</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tarek Alhamad, MD, MS, FACP, FASN</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert J Stratta, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel C Brennan, MD, FACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David M Nathan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 03, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3487101463"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Combined pancreas-kidney transplantation is an established treatment for selected patients with diabetes and end-stage kidney disease (ESKD). In the United States, more than 85 percent of pancreas transplants are performed as simultaneous pancreas-kidney (SPK) transplants, with the remainder performed as either sequential pancreas after kidney (PAK) transplants or pancreas transplants alone (PTA) [<a href="#rid1">1</a>].</p><p>This topic reviews surgical considerations and immunosuppression for SPK or PAK transplantation in patients with insulin-requiring diabetes mellitus and ESKD. Other aspects of pancreas-kidney transplantation are discussed elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7313.html" rel="external">"Pancreas-kidney transplantation in diabetes mellitus: Benefits and complications"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7305.html" rel="external">"Pancreas-kidney transplantation in diabetes mellitus: Patient selection and pretransplant evaluation"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/102979.html" rel="external">"Pancreas allograft rejection"</a>.)</p><p></p><p>The roles of PTA and islet transplantation in patients with diabetes who do not have kidney failure are discussed separately. (See  <a class="medical medical_review" href="/d/html/1767.html" rel="external">"Pancreas and islet transplantation in diabetes mellitus"</a>.)</p><p class="headingAnchor" id="H820853994"><span class="h1">SURGICAL CONSIDERATIONS</span><span class="headingEndMark"> — </span>In the United States, the most common technique for simultaneous pancreas-kidney (SPK) transplantation consists of placing both organs intraperitoneally through a vertical lower-midline incision. This technique preserves all possible options for transplantation of the pancreas as well as simultaneous placement of the kidney. In general, midline incisions are associated with fewer wound infections, although the key concepts are taking advantage of the intraperitoneal lymphatic circulation and permeability for internal absorption of peripancreatic secretions in conjunction with preventing proximity between the healing wound and the reperfused pancreas [<a href="#rid2">2</a>]. Centers differ in regards to either contralateral or ipsilateral placement of the organs as well as the surgical management of the exocrine pancreas secretions and the venous outflow. The majority of pancreas transplants are placed on the right side of the pelvis and performed with enteric exocrine drainage (≥90 percent) and systemic venous drainage (ie, from the graft portal vein either to the right iliac vein or distal inferior vena cava), while a minority of cases are performed with bladder exocrine drainage, using the right external iliac artery and vein for vascularization [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H103855277"><span class="h2">Organ placement</span><span class="headingEndMark"> — </span>Historically, the kidney was transplanted to the left and the pancreas to the right iliac vessels. Although some centers continue to practice this time-honored bilateral or contralateral technique, other centers have switched to placing the pancreas and kidney both on the right side with the pancreas transplanted first (to minimize cold ischemia time [CIT]) on the distal inferior vena cava/right common iliac vein and artery followed by the kidney transplanted more distally on the right external iliac vein and artery [<a href="#rid4">4</a>]. This ipsilateral technique preserves the left side for future transplantation and reduces operating time because the vascular dissection is localized to the right side only.</p><p>In planning for patients undergoing sequential pancreas after kidney (PAK) transplantation, it is preferable to transplant the kidney (either from a living or deceased donor) through an extraperitoneal approach on the left side (using a conventional kidney transplant incision) so that the right side remains available for subsequent PAK transplantation. However, similar to SPK transplantation, PAK transplantation is most commonly performed through a lower-midline intraperitoneal approach with the pancreas transplanted on the right side. For patients with a kidney transplant in situ on the right side, a PAK transplant can still be performed safely and successfully on the right side with the pancreas placed proximally and intraperitoneally while the kidney remains more distal and extraperitoneal on the right iliac vessels [<a href="#rid5">5</a>]. Because the inferior vena cava is on the right side and exposure of the right common iliac artery and vein is easier anatomically than isolating the left common iliac artery and vein, most surgeons prefer to place the pancreas on the right side irrespective of the position of the kidney transplant. Historically, there were data to suggest that placement of the pancreas on the left side had a higher rate of thrombosis, but little data exist in the past 20 years to either confirm or refute this observation, because nearly all pancreas transplants are placed on the right side.</p><p class="headingAnchor" id="H596910887"><span class="h2">Perioperative anticoagulation</span><span class="headingEndMark"> — </span>Unlike a kidney, a pancreas is an inherently low-microcirculatory-flow organ with a blood supply based on collateral (splenic and mesenteric) circulation. Consequently, the risk of early thrombosis (usually venous thrombosis) is much higher for the pancreas compared with other solid organ transplants. For patients undergoing SPK transplantation in the presence of end-stage kidney disease (ESKD), the presence of uremia (with its corresponding antiplatelet and anticoagulation effects) is in part protective against early pancreas allograft thrombosis. However, in the setting of preemptive SPK transplantation or PAK transplantation (in the absence of uremia), the risk of early pancreas thrombosis is higher. In addition, patients with longstanding diabetes may have significant vascular disease as well as inherent hypercoagulable defects. Consequently, many centers have included thrombophilia screening in the pretransplant evaluation of SPK transplant candidates. (See  <a class="medical medical_review" href="/d/html/7305.html" rel="external">"Pancreas-kidney transplantation in diabetes mellitus: Patient selection and pretransplant evaluation", section on 'Hypercoagulability evaluation'</a>.)</p><p>Accordingly, the judicious use of perioperative anticoagulation plays an important role in pancreas transplantation [<a href="#rid6">6</a>]. At a minimum, most centers use <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> or other antiplatelet agents in the immediate perioperative and postoperative period. At a maximum, some centers administer full therapeutic anticoagulation for a specified duration (one to four weeks). In general, however, most centers use some form of perioperative anticoagulation prophylaxis for a limited period (usually one to two weeks). Because the risk of early thrombosis is inherently much higher in PAK and pancreas transplant alone (PTA) compared with SPK transplantation, either low-dose unfractionated or low-molecular-weight heparin is used routinely in this setting with or without subsequent conversion to consolidation therapy with an oral agent. However, wide variation exists in perioperative anticoagulation protocols, and the risk of bleeding resulting in relaparotomy is not trivial in protocols that involve full therapeutic anticoagulation for an extended duration.</p><p>Keys to managing early graft thrombosis include not only prevention but also risk stratification and early diagnosis. Many centers perform surveillance imaging immediately following SPK transplantation including duplex ultrasonography with contrast-enhanced ultrasonography or computed tomography scanning with intravenous (IV) contrast reserved for abnormal screening ultrasound examinations or clinical indications (either graft dysfunction or severe pancreatitis) [<a href="#rid7">7-11</a>]. Grading or scoring systems have been developed to quantitate not only the degree, severity, and location of thrombosis but also to guide decision-making with respect to nonoperative or operative management. Partial vascular thrombosis is not uncommon following SPK transplantation and can often be managed with anticoagulation alone or in combination with endovascular techniques.</p><p class="headingAnchor" id="H3955186656"><span class="h2">Bladder versus enteric exocrine drainage</span><span class="headingEndMark"> — </span>One important surgical consideration during pancreas transplantation is the method of drainage of the pancreatic ductal (exocrine) secretions. Historically, management of the exocrine pancreas secretions was most commonly accomplished by bladder drainage [<a href="#rid12">12</a>], whereby the allograft duodenum is anastomosed side-to-side to the recipient's bladder. This technique was developed primarily to reduce the morbidity associated with exocrine leaks and accounted for &gt;90 percent of cases through 1995. However, since 1995, the preferred duct management technique has become enteric drainage with anastomosis of the donor duodenum to the recipient small bowel (either jejunum or ileum), with or without a diverting Roux-en-Y limb (used in approximately 15 percent of cases). A few centers use the recipient duodenum or even the stomach for exocrine drainage so that endoscopic surveillance and biopsy of either the allograft duodenum or pancreas can occur [<a href="#rid13">13-17</a>].</p><p>A major advantage of bladder drainage is the ability to use urine amylase to monitor for rejection in solitary pancreas transplants (either PAK or PTA). In PAK transplants, because the kidney transplant is performed from a different donor, the kidney cannot be used reliably as a marker for pancreas rejection. With SPK transplants from a single donor, the serum creatinine is used to monitor for kidney rejection, which may provide a surrogate marker for pancreas rejection. However, isolated rejection of the pancreas without kidney involvement (or isolated rejection of the kidney without pancreas involvement) may occur in SPK transplantation [<a href="#rid18">18</a>]. </p><p>Patient and allograft survival rates appear to be similar with either bladder or enteric exocrine drainage. Enteric exocrine drainage is superior in terms of reducing the incidence of metabolic and bladder-related complications [<a href="#rid13">13-15,19-25</a>]. As an example, a survey of 102 articles of both SPK transplants and PTAs found that urological complications were significantly more frequent with bladder versus enteric drainage (62 to 63 versus 12 to 20 percent) [<a href="#rid23">23</a>]. In addition, a retrospective study of 71 SPK transplant patients found that, compared with bladder drainage, enteric drainage resulted in a significantly lower incidence of volume depletion (3 versus 34 percent), acidosis (0 versus 41 percent), pancreatitis (3 versus 40 percent), and urinary tract infection (27 versus 71 percent), although patient and pancreas allograft survival rates were similar [<a href="#rid22">22</a>]. According to the International Pancreas Transplant Registry (IPTR), in bladder-drained pancreas recipients performed between 2000 and 2004, enteric conversion (open re-operative "switching" from bladder to enteric exocrine drainage) was required in 9 and 17 percent at one and three years posttransplant, respectively [<a href="#rid12">12</a>].</p><p>In a registry study of the United Network for Organ Sharing (UNOS) database, patients who underwent pancreas transplantation with enteric exocrine drainage without a diverting Roux limb had increased long-term patient and graft survival rates compared with those who underwent either enteric drainage with a Roux limb or those who underwent bladder drainage [<a href="#rid15">15</a>]. Other studies of bladder drainage have reported long-term enteric conversion rates of 42 and 44 percent, respectively [<a href="#rid24">24,25</a>]. In the former study, kidney and pancreas graft survival rates were not affected by enteric conversion, whereas in the latter study, enteric conversion was associated with an increased risk of acute rejection but did not increase the risk of graft loss or mortality.</p><p class="headingAnchor" id="H1192429820"><span class="h2">Portal versus systemic venous drainage</span><span class="headingEndMark"> — </span>Another important surgical consideration during pancreas transplantation involves the location of venous drainage of the pancreas allograft. Venous drainage is important because venous thrombosis is the most common early technical complication of pancreas transplantation. In addition, the method of venous drainage determines the site where insulin is initially released into the circulation. As an example, if the portal vein of the pancreas allograft is anastomosed to the recipient's inferior vena cava or iliac vein, then "systemic hyperinsulinemia" occurs [<a href="#rid26">26</a>]. By contrast, with techniques of venous drainage that involve the recipient's splanchnic venous system (usually the superior mesenteric vein), then "portal hyperinsulinemia" occurs with subsequent "first-pass" hepatic degradation or elimination of insulin, which is more "physiologic" and mimics the native pancreas. Despite the theoretical concerns, in metabolic studies, systemic hyperinsulinemia associated with systemic venous drainage has not been shown to be a risk factor for either insulin resistance or the metabolic syndrome. Conversely, metabolic studies following portal venous drainage of the pancreas allograft have failed to show any consistent long-term benefit of this technique [<a href="#rid13">13,14,27</a>].</p><p>After procurement, the dual arterial supply of the pancreas is usually reconstructed with a Y-graft, derived from the donor iliac artery bifurcation [<a href="#rid28">28,29</a>]. The donor internal iliac or hypogastric artery is usually anastomosed end-to-end to the splenic artery, and the external iliac artery is anastomosed end-to-end to the superior mesenteric artery (or vice versa). The donor Y-graft is then anastomosed end-to-side to the recipient's right common or external iliac artery. In the majority of pancreas transplants, the graft portal vein is anastomosed to the recipient's iliac vein (either right external or common iliac vein) or distal inferior vena cava (systemic venous drainage). In approximately 10 to 20 percent of cases, the graft portal vein is anastomosed to the recipient's superior mesenteric vein (portal venous drainage) [<a href="#rid13">13,26</a>]. In 2015, 82 percent of SPK and 92 percent of PAK transplants in the United States were performed with systemic venous drainage [<a href="#rid30">30</a>].</p><p>Patient and allograft survival rates appear to be similar with either systemic or portal venous drainage [<a href="#rid13">13,14,19,31-33</a>]. Portal venous drainage does not appear to offer any significant metabolic or immunologic benefits and is associated with comparable outcomes [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H1422913078"><span class="h2">Cold ischemia time</span><span class="headingEndMark"> — </span>Preservation time of up to 20 hours in University of Wisconsin (UW) solution had no untoward effects on short- or long-term pancreas graft survival in earlier studies [<a href="#rid34">34</a>]. In a subsequent study, however, preservation time exceeding 20 hours was associated with a higher risk of early technical failure [<a href="#rid35">35</a>]. Many centers target CITs of less than 12 hours, given the association of longer CIT with the development of graft pancreatitis and early graft thrombosis. The "12-hour rule" was validated in a study that demonstrated a stepwise increase in early technical graft failures and decrease in long-term, death-censored pancreas graft survival associated with progressively longer CITs [<a href="#rid36">36</a>]. Consequently, in SPK transplantation, the pancreas is often transplanted before the kidney to minimize CIT.</p><p class="headingAnchor" id="H701598330"><span class="h2">Segmental pancreas donation</span><span class="headingEndMark"> — </span>With segmental pancreas donation, a segment of pancreas (the body and tail) is donated by a living donor who is willing to undergo a hemipancreatectomy, and, in some countries, segments from cadaveric donors have been used. Live pancreas donation is associated with a finite risk of surgical and medical complications for the donors. Among 47 donors, 11 percent required transfusion, and 11 percent underwent splenectomy during the operation [<a href="#rid37">37,38</a>]. Postoperatively, 13 percent of donors developed a pseudocyst, and 9 percent had splenic infarct requiring splenectomy. In terms of medical complications, 26 percent developed new-onset diabetes requiring medication or insulin, 28 percent developed dyslipidemia, and 22 percent had hypertension at a median follow-up of 12 years.</p><p>In one case of living donation, a patient who had been diabetic for 17 years received a segment of pancreas from an identical twin [<a href="#rid39">39</a>]. No immunosuppressive therapy was given to prevent rejection. However, within two weeks, there was insulitis with lymphocytic infiltration of the beta cells in the grafted segment, indicative of recurrence of autoimmune diabetes in the transplanted tissue.</p><p class="headingAnchor" id="H1997687676"><span class="h2">Robotic pancreas transplantation</span><span class="headingEndMark"> — </span>An exciting innovation in pancreas transplantation is the description of laparoscopic pancreas transplantation under robotic assistance [<a href="#rid40">40,41</a>]. A report of the first three whole pancreas transplants performed with the assistance of the da Vinci Surgical System proved the feasibility of robotic-assisted laparoscopic surgery in pancreas transplantation [<a href="#rid40">40</a>]. In these cases, enteric drainage of the pancreas was created using an end-to-end circular stapler to anastomose the donor duodenum to the proximal small bowel of the recipient. However, the authors of this study have raised concerns regarding the effects of increased warm ischemia time on graft viability, although all three patients did well. Another study reported robotic-assisted pancreas transplants in 10 cases and concluded that this approach may have advantages in patients with diabetes and obesity [<a href="#rid41">41</a>]. Although numerous variations exist in the basic surgical techniques of pancreas transplantation and nuances continue to be described, current philosophy dictates that the most appropriate technique to be performed is the one with which the individual surgeon feels most comfortable based upon donor pancreas quality and recipient anatomic considerations.</p><p class="headingAnchor" id="H2229878526"><span class="h1">IMMUNOSUPPRESSION</span><span class="headingEndMark"> — </span>Immunosuppression regimens continue to change over time, with variations from center to center. The use of biologic agents for induction coupled with combinations of multiple agents with different mechanisms of action for maintenance therapy has become the standard of care in contemporary immunosuppression. These regimens accomplish the primary goals of immunosuppression, which are to achieve effective control of acute rejection while minimizing safety and tolerability risks for the patient and injury to the allograft(s).</p><p class="headingAnchor" id="H3909631939"><span class="h2">Induction therapy</span><span class="headingEndMark"> — </span>Most transplant centers advocate the use of induction therapy for all pancreas transplants [<a href="#rid3">3,12,30-33,42-48</a>]. Available agents for induction include T cell-depleting antibodies (such as polyclonal <a class="drug drug_general" data-topicid="10026" href="/d/drug information/10026.html" rel="external">rabbit antithymocyte globulin</a> [rATG]-Thymoglobulin and monoclonal <a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">alemtuzumab</a> [anti-CD52 antibody]) and nondepleting antibodies such as interleukin (IL)-2 receptor antibodies (monoclonal <a class="drug drug_general" data-topicid="8803" href="/d/drug information/8803.html" rel="external">basiliximab</a>). According to the 2016 Organ Procurement and Transplant Network (OPTN)/Scientific Registry of Transplant Recipients (SRTR) Annual Data Report, 85 percent of pancreas transplants performed in 2016 used T cell-depleting agents for induction; fewer than 10 percent of transplants used IL-2 receptor antibodies or reported no induction agent [<a href="#rid31">31</a>].</p><p>Induction therapy tends to be similar for recipients of either a simultaneous pancreas-kidney (SPK) transplant or a pancreas after kidney (PAK) transplant with the caveat that PAK transplantation, by definition, represents a second transplant. We, and most other transplant centers, administer a T cell-depleting agent (either multi-dose rATG-Thymoglobulin or single-dose <a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">alemtuzumab</a>) at the time of transplantation. We do <strong>not</strong> routinely use IL-2 receptor antibodies as induction therapy for SPK or PAK transplants due to concerns of a higher rate of acute rejection associated with pancreas transplantation in the absence of depleting antibody induction [<a href="#rid49">49,50</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>If rATG-Thymoglobulin is given, we administer intravenous (IV) rATG-Thymoglobulin 1 to 1.5 mg/kg intraoperatively (through either central or peripheral venous access). This initial intraoperative dose of rATG-Thymoglobulin is followed by 1.5 to 2 mg/kg of rATG-Thymoglobulin per day for the next two to three days for a total cumulative induction dose of 4.5 to 6 mg/kg. rATG-Thymoglobulin is administered if, at presentation, the white blood cell count is greater than 2000/microL and the platelet count is greater than 75,000/microL. If rATG-Thymoglobulin cannot be given, we administer <a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">alemtuzumab</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If <a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">alemtuzumab</a> is given, we administer alemtuzumab as a single IV (or subcutaneous) dose of 30 mg at the time of transplantation. We do not recommend administration of multiple doses of alemtuzumab, because this regimen has been associated with a high incidence of infection [<a href="#rid50">50,51</a>].</p><p></p><p>A lower rate of kidney allograft rejection following SPK transplantation has been observed with use of depleting induction agents [<a href="#rid42">42,44,45,47,48,52,53</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In one prospective, multicenter study, 174 SPK transplant recipients receiving <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a>, <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a>, and glucocorticoids for baseline immunosuppression were randomly assigned to induction (n = 87) or noninduction groups (n = 87) [<a href="#rid44">44</a>]. Any commercially available induction therapy could be used. At three years, kidney allograft survival was higher in the induction group compared with the noninduction group (92 versus 82 percent, respectively), and there was a trend toward increased biopsy-confirmed kidney rejection in the noninduction group compared with the induction group (28 versus 20 percent, respectively).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A randomized trial directly compared antithymocyte globulin, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, glucocorticoids, and delayed <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> to azathioprine, glucocorticoids, and cyclosporine among 50 type 1 diabetic patients undergoing SPK transplant [<a href="#rid42">42</a>]. A lower incidence of acute kidney allograft rejection episodes was observed among those randomly assigned to the antithymocyte globulin regimen (36 versus 76 percent).</p><p></p><p>The following studies compared individual induction agents in pancreas transplant:</p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective analysis of 128 SPK transplants performed between 2001 and 2008 compared outcomes between <a class="drug drug_general" data-topicid="8803" href="/d/drug information/8803.html" rel="external">basiliximab</a> (20 mg x two doses, n = 49) and multi-dose rATG (cumulative total 5 mg/kg, n = 79) [<a href="#rid49">49</a>]. rATG was associated with a decreased risk of rejection both at three months (6 versus 21 percent) and one year (14 versus 27 percent) posttransplant. Despite higher rates of rejection in the basiliximab group, both pancreas and kidney graft survival rates were similar at one year. Similarly, a separate retrospective analysis of 97 SPK transplants showed that overall and early T cell-mediated (cellular) rejection were more common with basiliximab (n = 38) than rATG (n = 59; 30 versus 14 percent and 21 versus 6 percent, respectively). No significant differences in either patient or one-, three-, or five-year pancreas allograft survival rates were observed [<a href="#rid54">54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">Alemtuzumab</a> and rATG induction were compared in a randomized, single-center trial of kidney and pancreas recipients [<a href="#rid55">55,56</a>]. Of the 222 patients enrolled, 46 received an SPK transplant (28 alemtuzumab, 18 rATG), and four received a PAK transplant (all received alemtuzumab). There were no significant differences between the alemtuzumab and rATG groups in five-year patient survival (82 versus 89 percent), kidney graft survival (79 versus 72 percent), or pancreas graft survival (64 versus 56 percent). Rates of acute rejection were lower in patients receiving alemtuzumab than in those receiving rATG (21 versus 44 percent, respectively), although this difference was not statistically significant. Cytomegalovirus (CMV) infections were significantly lower with alemtuzumab compared with rATG (0 versus 17 percent, respectively). In patients with functioning grafts, five-year mean serum creatinine, glomerular filtration rate (GFR), glycosylated hemoglobin, and C-peptide were similar between groups.</p><p></p><p>In addition, in the multicenter study cited above in which 174 SPK transplant recipients were randomly assigned to induction or noninduction, the lowest incidence of biopsy-proven acute rejection occurred in patients receiving T cell-depleting antibody compared with IL-2 receptor antibody induction (11 versus 24 percent, respectively), but this difference was not statistically significant [<a href="#rid44">44</a>].</p><p>T cell-depleting agents are more commonly used in pancreas transplantation compared with kidney transplantation (ie, 85 to 90 percent among pancreas transplants versus 75 percent for kidney transplants) [<a href="#rid3">3,31</a>]. This difference in practice is because there is an intrinsically higher acute rejection rate and greater difficulty in diagnosing rejection among pancreas transplant compared with kidney transplant recipients. Thus, most pancreas transplant centers believe that a greater amount of frontloaded immunosuppression, which is provided by T cell-depleting agents, is warranted in this setting.</p><p class="headingAnchor" id="H2545705308"><span class="h2">Maintenance therapy</span><span class="headingEndMark"> — </span>Following induction with a T cell-depleting agent (see <a class="local">'Induction therapy'</a> above), we administer maintenance immunosuppression therapy to all SPK and PAK transplant recipients. Maintenance immunosuppression is given to help prevent acute rejection and loss of the pancreas and kidney allografts. Maintenance therapy is similar for patients receiving an SPK or PAK transplant and typically includes a calcineurin inhibitor, an antimetabolite, and generally a tapering dose of glucocorticoids [<a href="#rid45">45-48</a>]. This approach is generally preferred by most transplant centers, although practice may vary from center to center and some centers individualize therapy based upon immunologic risk [<a href="#rid12">12,45-48</a>].</p><p class="headingAnchor" id="H637617998"><span class="h3">Maintenance regimen for SPK transplant recipients</span><span class="headingEndMark"> — </span>For most simultaneous pancreas-kidney (SPK) transplant recipients, we and others administer a maintenance regimen consisting of triple immunosuppression therapy. This includes a calcineurin inhibitor (usually <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a>), an antimetabolite (<a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a>), and <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> [<a href="#rid30">30-33,45-48</a>]. Most clinicians prefer triple maintenance therapy in SPK transplant recipients because of a purported higher risk of acute rejection in this setting compared with kidney transplantation alone. In addition, patients with diabetes who undergo SPK transplantation may have difficulty either achieving or tolerating therapeutic doses of individual drugs because of gastroparesis, erratic absorption, and diabetic enteropathy. By endorsing a three-drug regimen, adequate cumulative immunosuppression can be attained without incurring major specific-drug toxicities.</p><p class="headingAnchor" id="H2968684502"><span class="h4">Initiation of maintenance therapy</span><span class="headingEndMark"> — </span>Maintenance immunosuppression is initiated postoperatively and continued indefinitely. Because recipients of a pancreas transplant are typically "nil per os" (ie, NPO) for the first few days after surgery, maintenance immunosuppression during this period is generally administered IV or per nasogastric tube (using liquid suspensions when available) until patients are able to take oral medications on their own. Alternatively, <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> may be given sublingually as a powder.</p><p>In patients undergoing SPK and receiving induction therapy with rATG-Thymoglobulin or <a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">alemtuzumab</a>, we initiate maintenance immunosuppression therapy as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>We administer <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> on the evening of postoperative day 1 with immediate-release tacrolimus 1 to 2 mg twice daily, with doses adjusted to achieve a 12-hour trough level of 8 to 10 ng/mL for the first three months posttransplant and 6 to 8 ng/mL thereafter. Alternatively, some centers give extended-release tacrolimus tablets on postoperative day 1 at 0.08 mg/kg once per day, with doses adjusted to achieve the same 12-hour trough levels as with immediate-release tacrolimus. (See <a class="local">'Selection of a calcineurin inhibitor'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We administer <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (MMF) 1000 mg IV twice daily or MMF liquid suspension 1000 mg twice daily per nasogastric tube starting on postoperative day 1. When the patient is able to take oral medications by mouth (typically on postoperative day 2 or 3), we switch from IV or liquid suspension MMF to either enteric-coated mycophenolate sodium (EC-MPS) 720 mg orally twice daily or MMF capsules 1000 mg orally twice daily. Some centers may use three to four times daily dosing with either IV or oral formulations as part of a loading regimen. (See <a class="local">'Selection of an antimetabolite agent'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We administer either IV <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> at 7 mg/kg (maximum dose of 500 mg) or IV <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> 100 mg in the operating room, followed by IV methylprednisolone 20 mg daily until the patient is able to take medications by mouth. We then switch to oral <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> (20 mg once daily for the first week after transplantation, then tapered to 5 mg daily by one to two months posttransplant). Some centers give additional high doses of IV glucocorticoids as premedication for subsequent doses of rATG-Thymoglobulin or as part of a loading regimen. (See <a class="local">'Dosing of glucocorticoids'</a> below.)</p><p></p><p>Practice may vary from center to center with regards to selection and dosing of a calcineurin inhibitor, antimetabolite, and glucocorticoids. At some centers, mTOR inhibitors are used either in addition to or in place of any of the above agents. Other centers endorse early glucocorticoid withdrawal or use different glucocorticoid-tapering regimens. (See <a class="local">'Less commonly used agents'</a> below.)</p><p class="headingAnchor" id="H1489591110"><span class="h4">Selection of a calcineurin inhibitor</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">Tacrolimus</a> and <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> selectively inhibit calcineurin, thereby inhibiting the transcription of IL-2 and several other cytokines in T cells. By inhibiting cytokine gene transcription, calcineurin inhibitors suppress T cell and T cell-dependent B cell activation. Tacrolimus is the most commonly used calcineurin inhibitor for maintenance therapy after SPK and PAK transplantation in the United States. In 2016, for example, tacrolimus was administered prior to hospital discharge in more than 95 percent of pancreas transplant recipients [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/d/html/7995.html" rel="external">"Pharmacology of cyclosporine and tacrolimus"</a>.)</p><p>In most patients undergoing SPK transplant, we administer <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> rather than <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> because it is associated with equivalent or better pancreas survival, less acute rejection, less nephrotoxicity, and fewer cosmetic side effects [<a href="#rid45">45-48,57-61</a>]. A study that compared immediate to extended-release tacrolimus in stable SPK transplant recipients reported no differences in tacrolimus levels or outcomes [<a href="#rid62">62</a>]. The dosing of tacrolimus is discussed elsewhere in this topic. (See <a class="local">'Initiation of maintenance therapy'</a> above.)</p><p>We do not routinely give <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> as a calcineurin inhibitor to SPK or PAK transplant recipients; however, cyclosporine may be used in patients who have a history of prior allergy or intolerance to <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a>. In addition, many transplant centers outside of the United States (including Europe) continue to administer cyclosporine. Cyclosporine is initiated with doses adjusted to achieve a 12-hour trough level of 250 to 350 ng/mL (or peak level of 1000 to 1200 ng/mL) in the first three months posttransplant and 150 to 250 ng/mL (or peak level of 600 to 800 ng/mL) thereafter [<a href="#rid57">57-59</a>].</p><p>Similar graft survival outcomes have been observed with tacrolimus- and cyclosporine-based maintenance regimens [<a href="#rid58">58,59</a>]. However, some data suggest that pancreatic graft survival is higher with <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> [<a href="#rid57">57</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In the Euro-SPK 001 trial, 205 SPK transplant patients were randomly assigned to MMF plus glucocorticoids and either <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> or <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> [<a href="#rid57">57</a>]. At one year, both groups had similar patient and kidney allograft survival rates, with pancreas survival being significantly higher with tacrolimus (91 versus 75 percent). At three years, although patient and kidney survival rates were similar, pancreas survival remained significantly higher with tacrolimus (90 versus 72 percent), with pancreas allograft loss due to thrombosis being markedly increased with cyclosporine (10 versus 2 patients) [<a href="#rid58">58</a>]. In addition, an increased number of initial rejection episodes that were moderate or severe were observed with cyclosporine (28 versus 3 percent). Adverse events were largely similar between the two groups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In one study, 33 SPK transplant patients were randomly assigned to either <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> or <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, each given in combination with <a class="drug drug_general" data-topicid="8803" href="/d/drug information/8803.html" rel="external">basiliximab</a> (for induction therapy), glucocorticoids, and MMF [<a href="#rid59">59</a>]. With a median follow-up of approximately 16 months, one-year patient, pancreas, and kidney survival rates were each 94 percent with cyclosporine and 100 percent with tacrolimus.</p><p></p><p><a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">Tacrolimus</a> may be associated with an increased incidence of diabetes compared with <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, which has been noted in nondiabetic recipients of kidney allografts (see  <a class="medical medical_review" href="/d/html/7327.html" rel="external">"Kidney transplantation in adults: Posttransplantation diabetes mellitus"</a>). However, no obvious diabetogenic effects of tacrolimus have been documented in pancreas recipients [<a href="#rid58">58,60-64</a>]. As an example, among 136 type 1 diabetics who underwent successful SPK transplant and received either a cyclosporine- or tacrolimus-based regimen, glycemic status was the same in both groups as determined early (three months) and late (three years) after transplantation [<a href="#rid63">63</a>]. In a separate study of 674 pancreas transplant recipients, the incidence of redevelopment of diabetes at 10 years was not increased in those receiving tacrolimus compared with cyclosporine [<a href="#rid64">64</a>]. The possibility of glucocorticoid sparing or minimization with tacrolimus compared with cyclosporine may counteract some of the purported diabetogenic effects of tacrolimus.</p><p>As previously mentioned, the addition of induction therapy to a tacrolimus-based regimen may improve pancreas allograft survival [<a href="#rid44">44</a>]. However, it may also increase the risk of CMV viremia and syndrome. In addition, there has also been a reported 4 percent incidence of posttransplant lymphoproliferative disorder in pancreas transplant recipients [<a href="#rid12">12,60</a>]. (See  <a class="medical medical_review" href="/d/html/7335.html" rel="external">"Treatment and prevention of post-transplant lymphoproliferative disorders"</a>.)</p><p>Several drugs may interfere with the metabolism of <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> or <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, thereby causing either overdosing, with deterioration of kidney function, or underdosing, with an increased incidence of rejection. These issues are discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/d/html/7356.html" rel="external">"Kidney transplantation in adults: Maintenance immunosuppressive therapy"</a>.)</p><p class="headingAnchor" id="H2367859287"><span class="h4">Selection of an antimetabolite agent</span><span class="headingEndMark"> — </span>Antimetabolite agents interfere with the synthesis of nucleic acids and inhibit the proliferation of both T and B cells. MMF or EC-MPS is the antimetabolite agent used in 94 percent of pancreas transplant recipients in the United States; <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> is rarely used as primary therapy [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/d/html/7990.html" rel="external">"Mycophenolate: Overview of use and adverse effects in the treatment of rheumatic diseases", section on 'Pharmacology'</a> and  <a class="medical medical_review" href="/d/html/7994.html" rel="external">"Pharmacology and side effects of azathioprine when used in rheumatic diseases", section on 'Pharmacology and biologic effects'</a>.)</p><p>Most transplant centers administer <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> (MMF or EC-MPS) as an antimetabolite agent to SPK recipients rather than <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>. MMF, compared with azathioprine in both cyclosporine- and tacrolimus-based regimens, has been associated with more than a 50 percent reduction in the incidence and severity of acute T cell-mediated rejection [<a href="#rid43">43,65-69</a>].</p><p>There is also evidence that MMF results in enhanced graft survival [<a href="#rid66">66,67,69</a>]. A retrospective study evaluated the outcomes of 358 consecutive SPK transplant patients who received either MMF or <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> in combination with a cyclosporine-based regimen [<a href="#rid67">67</a>]. At two years after transplantation, superior survival rates were observed among the MMF group for both the kidney (95 versus 86 percent) and pancreas allografts (95 versus 83 percent).</p><p>However, many patients discontinue MMF due to gastrointestinal intolerance. In one series of 120 patients, the frequency of conversion (principally because of gastrointestinal toxicity) from MMF to <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> at one year after transplantation was 14, 26, and 39 percent in those who had undergone SPK transplant, PAK transplant, and pancreas transplant alone (PTA), respectively [<a href="#rid68">68</a>]. Most centers manage the purported synergistic gastrointestinal toxicity of the <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> and MMF combination with either stepwise dose reduction of each agent, changing MMF interval dosing to three to four times daily, or separating the time of administration of tacrolimus and MMF by one to two hours. In another study, however, the administration of high-dose <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> (1000 mg three-times daily versus twice daily) was associated with improved pancreas graft survival, although dose reductions because of tolerability were common in both groups [<a href="#rid69">69</a>].</p><p>The formulation of EC-MPS delays the release of <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> acid until the small intestine [<a href="#rid70">70</a>]. EC-MPS shows fewer gastrointestinal side effects, and conversion from MMF [<a href="#rid70">70</a>] to EC-MPS has been associated with improved gastrointestinal tolerability in kidney and SPK transplant recipients [<a href="#rid71">71-73</a>]. Thus, conversion to EC-MPS is a reasonable option and should be considered first, before switching to <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, if none of the above maneuvers are successful. However, because of gastroparesis and diabetic enteropathy, it is not uncommon for SPK and PAK transplant recipients to have problems tolerating therapeutic doses of the drug combination of <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> and MMF/EC-MPS because of gastrointestinal side effects. In addition, MMF/EC-MPS dose reductions may occur in the setting of infection or cytopenias. Some data suggest that dose changes or reductions in either tacrolimus or MMF/EC-MPS (independent of conversion to another immunosuppressant) may be associated with a higher incidence of acute rejection. For this reason, some centers prefer to continue glucocorticoids long term (or add an mTOR inhibitor) to provide an adequate level of chronic immunosuppression in the setting of dose reduction of the primary immunosuppressants.</p><p><a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">Mycophenolate</a> is teratogenic, and its use is contraindicated in pregnancy. In female recipients of childbearing age, we administer mycophenolate as the antimetabolite agent and counsel them against getting pregnant for at least one to two years posttransplant. After this time, if patients wish to conceive, we switch them to <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, which does not seem to have a detrimental effect on fertility or pregnancy [<a href="#rid74">74</a>]. Practice may vary at other transplant centers, and some clinicians do not use mycophenolate in any female recipients of childbearing age unless they are on long-acting contraception, have undergone surgical sterilization procedures, or have absolute infertility.</p><p>The dosing of MMF and EC-MPS is discussed above. (See <a class="local">'Initiation of maintenance therapy'</a> above.)</p><p class="headingAnchor" id="H546878080"><span class="h4">Dosing of glucocorticoids</span><span class="headingEndMark"> — </span>There is no consensus on the optimal dose or maintenance schedule of glucocorticoids following SPK transplantation. As part of a triple-agent regimen, we administer IV <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> at 7 mg/kg (maximum of 500 mg) in the operating room, followed by IV methylprednisolone 20 mg daily until the patient is able to take medications by mouth. Other centers may prefer to use IV <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (up to 100 mg) perioperatively followed by IV and then oral methylprednisolone. We then switch to oral <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 20 mg once daily for the first week after transplantation. The daily dose is then tapered every week by 5 mg, resulting in 15 mg daily for one week, 10 mg daily for one week, and then 5 mg daily. In the absence of acute rejection, we generally reduce glucocorticoids to a dose of 5 mg daily by one month following SPK transplant. Dosing and tapering of glucocorticoids may vary among transplant centers.</p><p>The use of long-term glucocorticoids may also vary from center to center, and some centers prefer early glucocorticoid withdrawal in some SPK recipients. In this setting, some centers may use an mTOR inhibitor as a third maintenance immunosuppressive agent while others manage patients long term with dual (<a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> and <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a>) therapy. According to the OPTN/SRTR Annual Data Report from 2016, approximately 73 percent of pancreas transplant recipients were on glucocorticoid maintenance at one year posttransplant [<a href="#rid31">31</a>].</p><p>There is insufficient evidence for the benefits and harms of continued glucocorticoids in pancreas transplantation [<a href="#rid75">75</a>]. However, a number of centers have reported success with either glucocorticoid elimination or rapid glucocorticoid withdrawal in SPK transplant recipients, particularly in the setting of depleting antibody induction therapy [<a href="#rid76">76-80</a>].</p><p class="headingAnchor" id="H1185104093"><span class="h4">Less commonly used agents</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>mTOR inhibitors</strong> – The use of mTOR inhibitors (<a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a>, <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a>) at the time of pancreas transplantation has been steadily decreasing over the past decade, from approximately 20 percent in 2006 to 10 percent in 2016. A similar trend is noted in the number of recipients who are receiving mTOR inhibitors at one-year follow-up [<a href="#rid31">31</a>]. The mechanism of action of mTOR inhibitors is inhibition of protein kinase-mediated signaling pathways, which regulate cell growth, proliferation, and cell cycle progression. In addition to immunosuppressive effects, mTOR inhibitors have anti-tumor, anti-viral, and anti-fungal properties. The mTOR inhibitors function through a targeting pathway that is unique from either calcineurin inhibitors or antimetabolites, which represents another rationale for their use. Sirolimus is administered once daily because of a long half-life, and everolimus is administered twice daily; both agents are dosed to achieve target trough levels of 3 to 8 ng/mL:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A single-center study reported one-year kidney and pancreas survival rates of 100 percent among 20 SPK transplant patients administered a <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a>/<a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> maintenance regimen after induction therapy that also included rATG-Thymoglobulin and a rapid glucocorticoid taper [<a href="#rid76">76</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In one study of 59 SPK transplant recipients, two prednisone-free tacrolimus-based regimens were compared [<a href="#rid77">77</a>]. Both groups received rATG-Thymoglobulin induction. At six years posttransplant, patients who received <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> plus <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> (n = 37) had a lower rate of kidney survival compared with those who received tacrolimus plus MMF (n = 22; 71 versus 91 percent), although the difference was not statistically significant. Rates of death-censored pancreas survival and biopsy-proven acute T cell-mediated rejection were similar between both groups.</p><p></p><p class="bulletIndent1">A United Network for Organ Sharing (UNOS) registry study spanning 1986 to 2016 stratified 25,387 pancreas or SPK transplant recipients into two groups according to those who either received mTOR inhibitors (at any time posttransplant; n = 4174) or those remaining (n = 21,663) who were managed exclusively with non-mTOR inhibitor-based immunosuppression [<a href="#rid78">78</a>]. The use of mTOR inhibitors was associated with a 7 percent risk reduction in allograft failure and higher patient survival rates up to 10 years. By contrast, randomized, controlled trials comparing mTOR inhibitors with standard immunosuppressive regimens have yielded conflicting results [<a href="#rid81">81-83</a>].</p><p></p><p class="bulletIndent1">The available data suggest that the role of mTOR inhibitors may be better suited to replace an antimetabolite rather than a calcineurin inhibitor, which may then permit glucocorticoid weaning and withdrawal.</p><p></p><p class="bulletIndent1">Adverse effects including poor wound healing, edema, lymphocele formation, proteinuria, and dyslipidemia as well as synergistic nephrotoxicity when combined with calcineurin inhibitors, which may limit the utility of mTOR inhibitors in diabetic transplant recipients. A common theme in most studies with mTOR inhibitors has been a high incidence of drug-related side effects resulting in either dose reductions or discontinuation with conversion to another agent. (See  <a class="medical medical_review" href="/d/html/7329.html" rel="external">"Pharmacology of mammalian (mechanistic) target of rapamycin (mTOR) inhibitors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Belatacept</strong> – <a class="drug drug_general" data-topicid="16790" href="/d/drug information/16790.html" rel="external">Belatacept</a> is a soluble fusion protein that selectively blocks a T cell costimulation pathway, thereby limiting T cell activation. Although studied extensively in kidney transplantation, there are limited data in SPK transplantation. An open-label, multicenter, randomized trial of belatacept in SPK transplantation as a de novo maintenance agent (in combination with rATG induction and <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a>) in order to achieve calcineurin inhibitor and glucocorticoid withdrawal was stopped prematurely because of a high incidence of pancreas allograft rejection [<a href="#rid84">84</a>]. Previous attempts to attain calcineurin inhibitor and glucocorticoid withdrawal following SPK transplantation have likewise been met with difficulty [<a href="#rid51">51</a>].</p><p></p><p class="headingAnchor" id="H2446569354"><span class="h3">Maintenance regimen for PAK transplant recipients</span><span class="headingEndMark"> — </span>At the time of pancreas after kidney (PAK) transplantation, patients are already receiving maintenance immunosuppression to prevent rejection of the previous kidney allograft. If the patient is already on a triple immunosuppression regimen consisting of <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a>, MMF or EC-MPS, and <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>, we typically do not modify the maintenance regimen if kidney allograft function is stable and the patient is tolerating the maintenance regimen without significant adverse effects.</p><p>However, given the higher immunogenicity of the transplanted pancreas, many patients may require a modification of their maintenance regimen to augment immunosuppression following pancreas transplant. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In patients who are on <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> and are being maintained at 12-hour trough levels of 3 to 7 ng/mL, we adjust the dose to target higher trough levels of 8 to 10 ng/mL for the first three months following PAK transplant, then 6 to 8 ng/mL thereafter.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients who are receiving reduced doses of MMF (ie, 500 mg twice daily) or EC-MPS (ie, 360 mg twice daily), we increase to full dose (ie, 1000 mg twice daily for MMF or 720 mg twice daily for EC-MPS).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients receiving <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, rather than <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a>, as a calcineurin inhibitor do not need to switch to tacrolimus if they have stable kidney allograft function and are not experiencing significant adverse effects. However, some clinicians prefer tacrolimus and will advise their patients to switch from cyclosporine to tacrolimus at the time of PAK transplant unless the patient is taking cyclosporine because of intolerance to tacrolimus. If cyclosporine is continued following PAK transplant, then higher levels (similar to those following SPK transplant) are targeted for the first few months posttransplant.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients who are already on glucocorticoids, we initiate a "steroid recycle" at the time of PAK transplant (IV high-dose glucocorticoids perioperatively, then <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 20 mg daily with a taper to 5 mg daily by one to two months posttransplant).</p><p></p><p>However, similar to SPK transplantation, many variations exist on dosing and target levels of all of the above immunosuppressants based upon center practice patterns and individualized immunological risk.</p><p class="headingAnchor" id="H59146077"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110754.html" rel="external">"Society guideline links: Kidney transplantation"</a>.)</p><p class="headingAnchor" id="H102387288"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles </strong>– Combined pancreas-kidney transplantation is an established treatment for selected patients with diabetes and end-stage kidney disease (ESKD). Pancreas transplants are performed as simultaneous pancreas-kidney (SPK) transplants (most common), sequential pancreas after kidney (PAK) transplants, or pancreas transplants alone (PTAs). (See  <a class="medical medical_review" href="/d/html/7305.html" rel="external">"Pancreas-kidney transplantation in diabetes mellitus: Patient selection and pretransplant evaluation", section on 'Introduction'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgical considerations </strong>– In the United States, the most common technique for SPK transplantation consists of placing both organs intraperitoneally through a vertical midline incision. Centers differ in regards to either contralateral or ipsilateral placement of the organs as well as the surgical management of the exocrine pancreas secretions and the venous outflow. The majority of pancreas transplants are placed on the right side and performed with enteric exocrine drainage (≥90 percent) and systemic venous drainage (ie, from the graft portal vein either to the right iliac vein or distal inferior vena cava). (See <a class="local">'Surgical considerations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Induction immunosuppressive therapy </strong>– Among patients receiving either an SPK or PAK transplant, we recommend induction immunosuppression therapy that consists of an antibody plus standard triple immunosuppressive therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). In recipients of an SPK or PAK transplant, we suggest administration of a T cell-depleting agent (either <a class="drug drug_general" data-topicid="10026" href="/d/drug information/10026.html" rel="external">rabbit antithymocyte globulin</a> [rATG]-Thymoglobulin or <a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">alemtuzumab</a>) rather than a nondepleting interleukin (IL)-2 receptor antagonist (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Induction therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maintenance immunosuppressive therapy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>SPK transplant recipients </strong>– In patients receiving an SPK transplant, we and most transplant centers administer a maintenance immunosuppression regimen consisting of triple immunosuppression therapy with a calcineurin inhibitor, an antimetabolite, and tapering doses of glucocorticoids (see <a class="local">'Maintenance therapy'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Among the available calcineurin inhibitors, we suggest the administration of <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> rather than <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Selection of a calcineurin inhibitor'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Among the available antimetabolite agents, we suggest the administration of <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> (mycophenolate mofetil [MMF] or enteric-coated mycophenolate sodium [EC-MPS]) rather than <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Selection of an antimetabolite agent'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For most patients, we administer glucocorticoids. We use oral <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> tapered to 5 mg daily by one to two months after transplantation. (See <a class="local">'Dosing of glucocorticoids'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>PAK transplant recipients </strong>– At the time of pancreas transplantation, most recipients of a PAK transplant are receiving maintenance immunosuppression to prevent rejection of the kidney allograft. If the patient is already on a triple immunosuppression regimen consisting of <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a>, MMF or EC-MPS, and <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>, we typically do not modify the maintenance regimen if kidney allograft function is stable and the patient is tolerating the maintenance regimen without significant adverse effects. However, given the higher immunogenicity of the transplanted pancreas, many patients may require a modification of their maintenance regimen to augment immunosuppression following pancreas transplant. (See <a class="local">'Maintenance regimen for PAK transplant recipients'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kandaswamy R, Stock PG, Miller J, et al. OPTN/SRTR 2020 Annual Data Report: Pancreas. Am J Transplant 2022; 22 Suppl 2:137.</a></li><li><a class="nounderline abstract_t">Douzdjian V, Gugliuzza KK. The impact of midline versus transverse incisions on wound complications and outcome in simultaneous pancreas-kidney transplants: a retrospective analysis. Transpl Int 1996; 9:62.</a></li><li><a class="nounderline abstract_t">Gruessner AC, Gruessner RWG. The Current State of Pancreas Transplantation in the USA—A Registry Report. Curr Transpl Rep 2018; 5:304.</a></li><li><a class="nounderline abstract_t">Fridell JA, Shah A, Milgrom ML, et al. Ipsilateral placement of simultaneous pancreas and kidney allografts. Transplantation 2004; 78:1074.</a></li><li><a class="nounderline abstract_t">Yin H, Arpali E, Leverson GE, et al. Ipsilateral versus contralateral placement of the pancreas allograft in pancreas after kidney transplant recipients. Clin Transplant 2018; 32:e13337.</a></li><li><a class="nounderline abstract_t">Farney AC, Rogers J, Stratta RJ. Pancreas graft thrombosis:  causes, prevention, diagnosis, and intervention. Curr Opin Organ Transplant 2012; 17:87.</a></li><li><a class="nounderline abstract_t">Kopp WH, van Leeuwen CAT, Lam HD, et al. Retrospective study on detection, treatment, and clinical outcome of graft thrombosis following pancreas transplantation. Transpl Int 2019; 32:410.</a></li><li><a class="nounderline abstract_t">Swensson J, Nagaraju S, O'Brien D, et al. Contrast-enhanced ultrasound of the transplant pancreas in the post-operative setting. Clin Transplant 2019; 33:e13733.</a></li><li><a class="nounderline abstract_t">Hakeem A, Chen J, Iype S, et al. Pancreatic allograft thrombosis: Suggestion for a CT grading system and management algorithm. Am J Transplant 2018; 18:163.</a></li><li><a class="nounderline abstract_t">Harbell JW, Morgan T, Feldstein VA, et al. Splenic Vein Thrombosis Following Pancreas Transplantation: Identification of Factors That Support Conservative Management. Am J Transplant 2017; 17:2955.</a></li><li><a class="nounderline abstract_t">Raveh Y, Ciancio G, Burke GW, et al. Susceptibility-directed anticoagulation after pancreas transplantation: A single-center retrospective study. Clin Transplant 2019; 33:e13619.</a></li><li><a class="nounderline abstract_t">Gruessner AC, Sutherland DE. Pancreas transplant outcomes for United States (US) and non-US cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR) as of June 2004. Clin Transplant 2005; 19:433.</a></li><li><a class="nounderline abstract_t">Rogers J, Farney AC, Orlando G, et al. Pancreas transplantation with portal venous drainage with an emphasis on technical aspects. Clin Transplant 2014; 28:16.</a></li><li><a class="nounderline abstract_t">El-Hennawy H, Stratta RJ, Smith F. Exocrine drainage in vascularized pancreas transplantation in the new millennium. World J Transplant 2016; 6:255.</a></li><li><a class="nounderline abstract_t">Siskind EJ, Amodu LI, Pinto S, et al. Bladder Versus Enteric Drainage of Exocrine Secretions in Pancreas Transplantation: A Retrospective Analysis of the United Network for Organ Sharing Database. Pancreas 2018; 47:625.</a></li><li><a class="nounderline abstract_t">Lindahl JP, Horneland R, Nordheim E, et al. Outcomes in Pancreas Transplantation With Exocrine Drainage Through a Duodenoduodenostomy Versus Duodenojejunostomy. Am J Transplant 2018; 18:154.</a></li><li><a class="nounderline abstract_t">Shokouh-Amiri H, Zakhary JM, Zibari GB. A novel technique of portal-endocrine and gastric-exocrine drainage in pancreatic transplantation. J Am Coll Surg 2011; 212:730.</a></li><li><a class="nounderline abstract_t">Parajuli S, Arpali E, Astor BC, et al. Concurrent biopsies of both grafts in recipients of simultaneous pancreas and kidney demonstrate high rates of discordance for rejection as well as discordance in type of rejection - a retrospective study. Transpl Int 2018; 31:32.</a></li><li><a class="nounderline abstract_t">Mai ML, Ahsan N, Gonwa T. The long-term management of pancreas transplantation. Transplantation 2006; 82:991.</a></li><li><a class="nounderline abstract_t">Gaber AO, Shokouh-Amiri MH, Hathaway DK, et al. Results of pancreas transplantation with portal venous and enteric drainage. Ann Surg 1995; 221:613.</a></li><li><a class="nounderline abstract_t">Kuo PC, Johnson LB, Schweitzer EJ, Bartlett ST. Simultaneous pancreas/kidney transplantation--a comparison of enteric and bladder drainage of exocrine pancreatic secretions. Transplantation 1997; 63:238.</a></li><li><a class="nounderline abstract_t">Bloom RD, Olivares M, Rehman L, et al. Long-term pancreas allograft outcome in simultaneous pancreas-kidney transplantation: a comparison of enteric and bladder drainage. Transplantation 1997; 64:1689.</a></li><li><a class="nounderline abstract_t">Demartines N, Schiesser M, Clavien PA. An evidence-based analysis of simultaneous pancreas-kidney and pancreas transplantation alone. Am J Transplant 2005; 5:2688.</a></li><li><a class="nounderline abstract_t">Adler JT, Zaborek N, Redfield RR 3rd, et al. Enteric conversion after bladder-drained pancreas transplantation is not associated with worse allograft survival. Am J Transplant 2019; 19:2543.</a></li><li><a class="nounderline abstract_t">Riad SM, Keys DO, Jackson S, et al. Enteric Conversion of Bladder-drained Pancreas as a Predictor of Outcomes in Almost 600 Recipients at a Single Center. Transplant Direct 2020; 6:e550.</a></li><li><a class="nounderline abstract_t">Diem P, Abid M, Redmon JB, et al. Systemic venous drainage of pancreas allografts as independent cause of hyperinsulinemia in type I diabetic recipients. Diabetes 1990; 39:534.</a></li><li><a class="nounderline abstract_t">Oliver JB, Beidas AK, Bongu A, et al. A comparison of long-term outcomes of portal versus systemic venous drainage in pancreatic transplantation: a systematic review and meta-analysis. Clin Transplant 2015; 29:882.</a></li><li><a class="nounderline abstract_t">Marsh CL, Perkins JD, Sutherland DE, et al. Combined hepatic and pancreaticoduodenal procurement for transplantation. Surg Gynecol Obstet 1989; 168:254.</a></li><li><a class="nounderline abstract_t">Fridell JA, Powelson JA, Sanders CE, et al. Preparation of the pancreas allograft for transplantation. Clin Transplant 2011; 25:E103.</a></li><li><a class="nounderline abstract_t">Gruessner AC. 2011 update on pancreas transplantation: comprehensive trend analysis of 25,000 cases followed up over the course of twenty-four years at the International Pancreas Transplant Registry (IPTR). Rev Diabet Stud 2011; 8:6.</a></li><li><a class="nounderline abstract_t">Kandaswamy R, Stock PG, Gustafson SK, et al. OPTN/SRTR 2016 Annual Data Report: Pancreas. Am J Transplant 2018; 18 Suppl 1:114.</a></li><li><a class="nounderline abstract_t">Gruessner AC, Gruessner RW. Pancreas Transplantation of US and Non-US Cases from 2005 to 2014 as Reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR). Rev Diabet Stud 2016; 13:35.</a></li><li><a class="nounderline abstract_t">Gruessner AC, Gruessner RWG. Pancreas Transplantation for Patients with Type 1 and Type 2 Diabetes Mellitus in the United States: A Registry Report. Gastroenterol Clin North Am 2018; 47:417.</a></li><li><a class="nounderline abstract_t">Morel P, Moudry-Munns K, Najarian JS, et al. Influence of preservation time on outcome and metabolic function of bladder-drained pancreas transplants. Transplantation 1990; 49:294.</a></li><li><a class="nounderline abstract_t">Finger EB, Radosevich DM, Dunn TB, et al. A composite risk model for predicting technical failure in pancreas transplantation. Am J Transplant 2013; 13:1840.</a></li><li><a class="nounderline abstract_t">Rudolph EN, Dunn TB, Sutherland DER, et al. Optimizing outcomes in pancreas transplantation: Impact of organ preservation time. Clin Transplant 2017; 31.</a></li><li><a class="nounderline abstract_t">Kirchner VA, Finger EB, Bellin MD, et al. Long-term Outcomes for Living Pancreas Donors in the Modern Era. Transplantation 2016; 100:1322.</a></li><li><a class="nounderline abstract_t">Boggi U, Amorese G, Marchetti P, Mosca F. Segmental live donor pancreas transplantation: review and critique of rationale, outcomes, and current recommendations. Clin Transplant 2011; 25:4.</a></li><li><a class="nounderline abstract_t">Sibley RK, Sutherland DE, Goetz F, Michael AF. Recurrent diabetes mellitus in the pancreas iso- and allograft. A light and electron microscopic and immunohistochemical analysis of four cases. Lab Invest 1985; 53:132.</a></li><li><a class="nounderline abstract_t">Boggi U, Signori S, Vistoli F, et al. Laparoscopic robot-assisted pancreas transplantation:  first world experience. Transplantation 2012; 93:201.</a></li><li><a class="nounderline abstract_t">Spaggiari M, Tulla KA, Okoye O, et al. The utility of robotic assisted pancreas transplants - a single center retrospective study. Transpl Int 2019; 32:1173.</a></li><li><a class="nounderline abstract_t">Cantarovich D, Karam G, Giral-Classe M, et al. Randomized comparison of triple therapy and antithymocyte globulin induction treatment after simultaneous pancreas-kidney transplantation. Kidney Int 1998; 54:1351.</a></li><li><a class="nounderline abstract_t">Stratta RJ. Simultaneous use of tacrolimus and mycophenolate mofetil in combined pancreas-kidney transplant recipients: a multi-center report. The FK/MMF Multi-Center Study Group. Transplant Proc 1997; 29:654.</a></li><li><a class="nounderline abstract_t">Burke GW 3rd, Kaufman DB, Millis JM, et al. Prospective, randomized trial of the effect of antibody induction in simultaneous pancreas and kidney transplantation: three-year results. Transplantation 2004; 77:1269.</a></li><li><a class="nounderline abstract_t">Heilman RL, Mazur MJ, Reddy KS. Immunosuppression in simultaneous pancreas-kidney transplantation: progress to date. Drugs 2010; 70:793.</a></li><li><a class="nounderline abstract_t">Kimelman M, Brandacher G. Trends in immunosuppression after pancreas transplantation:  what is in the pipeline? Curr Opin Organ Transplant 2013; 18:76.</a></li><li><a class="nounderline abstract_t">Niederhaus SV, Kaufman DB, Odorico JS. Induction therapy in pancreas transplantation. Transpl Int 2013; 26:704.</a></li><li><a class="nounderline abstract_t">Stratta RJ, Farney AC, Rogers J, Orlando G. Immunosuppression for pancreas transplantation with an emphasis on antibody induction strategies: review and perspective. Expert Rev Clin Immunol 2014; 10:117.</a></li><li><a class="nounderline abstract_t">Bazerbachi F, Selzner M, Boehnert MU, et al. Thymoglobulin versus basiliximab induction therapy for simultaneous kidney-pancreas transplantation: impact on rejection, graft function, and long-term outcome. Transplantation 2011; 92:1039.</a></li><li><a class="nounderline abstract_t">Magliocca JF, Odorico JS, Pirsch JD, et al. A comparison of alemtuzumab with basiliximab induction in simultaneous pancreas-kidney transplantation. Am J Transplant 2008; 8:1702.</a></li><li><a class="nounderline abstract_t">Gruessner RW, Kandaswamy R, Humar A, et al. Calcineurin inhibitor- and steroid-free immunosuppression in pancreas-kidney and solitary pancreas transplantation. Transplantation 2005; 79:1184.</a></li><li><a class="nounderline abstract_t">Reddy KS, Stratta RJ, Shokouh-Amiri H, et al. Simultaneous kidney-pancreas transplantation without antilymphocyte induction. Transplantation 2000; 69:49.</a></li><li><a class="nounderline abstract_t">Kaufman DB, Burke GW III, Bruce DS, et al. Prospective, randomized, multi-center trial of antibody induction therapy in simultaneous pancreas-kidney transplantation. Am J Transplant 2003; 3:855.</a></li><li><a class="nounderline abstract_t">Fernández-Burgos I, Montiel Casado MC, Pérez-Daga JA, et al. Induction therapy in simultaneous pancreas-kidney transplantation: thymoglobulin versus basiliximab. Transplant Proc 2015; 47:120.</a></li><li><a class="nounderline abstract_t">Farney AC, Doares W, Rogers J, et al. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation. Transplantation 2009; 88:810.</a></li><li><a class="nounderline abstract_t">Stratta RJ, Rogers J, Orlando G, et al. 5-year results of a prospective, randomized, single-center study of alemtuzumab compared with rabbit antithymocyte globulin induction in simultaneous kidney-pancreas transplantation. Transplant Proc 2014; 46:1928.</a></li><li><a class="nounderline abstract_t">Bechstein WO, Malaise J, Saudek F, et al. Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in primary simultaneous pancreas-kidney transplantation: 1-year results of a large multicenter trial. Transplantation 2004; 77:1221.</a></li><li><a class="nounderline abstract_t">Saudek F, Malaise J, Boucek P, et al. Efficacy and safety of tacrolimus compared with cyclosporin microemulsion in primary SPK transplantation: 3-year results of the Euro-SPK 001 trial. Nephrol Dial Transplant 2005; 20 Suppl 2:ii3.</a></li><li><a class="nounderline abstract_t">Boggi U, Vistoli F, Del Chiaro M, et al. Single-center, open, prospective, randomized pilot study comparing cyclosporine versus tacrolimus in simultaneous pancreas-kidney transplantation. Transplant Proc 2004; 36:1064.</a></li><li><a class="nounderline abstract_t">Gruessner RW, Burke GW, Stratta R, et al. A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation. Transplantation 1996; 61:261.</a></li><li><a class="nounderline abstract_t">Jordan ML, Shapiro R, Gritsch HA, et al. Long-term results of pancreas transplantation under tacrolius immunosuppression. Transplantation 1999; 67:266.</a></li><li><a class="nounderline abstract_t">Cattral M, Luke S, Knauer MJ, et al. Randomized open-label crossover assessment of Prograf vs Advagraf on immunosuppressant pharmacokinetics and pharmacodynamics in simultaneous pancreas-kidney patients. Clin Transplant 2018; 32.</a></li><li><a class="nounderline abstract_t">Dieterle CD, Schmauss S, Veitenhansl M, et al. Glucose metabolism after pancreas transplantation: cyclosporine versus tacrolimus. Transplantation 2004; 77:1561.</a></li><li><a class="nounderline abstract_t">Neidlinger N, Singh N, Klein C, et al. Incidence of and risk factors for posttransplant diabetes mellitus after pancreas transplantation. Am J Transplant 2010; 10:398.</a></li><li><a class="nounderline abstract_t">Stegall MD, Simon M, Wachs ME, et al. Mycophenolate mofetil decreases rejection in simultaneous pancreas-kidney transplantation when combined with tacrolimus or cyclosporine. Transplantation 1997; 64:1695.</a></li><li><a class="nounderline abstract_t">Merion RM, Henry ML, Melzer JS, et al. Randomized, prospective trial of mycophenolate mofetil versus azathioprine for prevention of acute renal allograft rejection after simultaneous kidney-pancreas transplantation. Transplantation 2000; 70:105.</a></li><li><a class="nounderline abstract_t">Odorico JS, Pirsch JD, Knechtle SJ, et al. A study comparing mycophenolate mofetil to azathioprine in simultaneous pancreas-kidney transplantation. Transplantation 1998; 66:1751.</a></li><li><a class="nounderline abstract_t">Gruessner RW, Sutherland DE, Drangstveit MB, et al. Mycophenolate mofetil in pancreas transplantation. Transplantation 1998; 66:318.</a></li><li><a class="nounderline abstract_t">Descourouez JL, Jorgenson MR, Menninga N, et al. Impact of intensive dosing of mycophenolate on pancreas allograft survival. Clin Transplant 2018; 32:e13293.</a></li><li><a class="nounderline abstract_t">van Hest RM, Mathot RA, Pescovitz MD, et al. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol 2006; 17:871.</a></li><li><a class="nounderline abstract_t">Bolin P, Tanriover B, Zibari GB, et al. Improvement in 3-month patient-reported gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients. Transplantation 2007; 84:1443.</a></li><li><a class="nounderline abstract_t">Chan L, Mulgaonkar S, Walker R, et al. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation 2006; 81:1290.</a></li><li><a class="nounderline abstract_t">Belliere J, Esposito L, Gandia P, et al. Comparison of the exposure of mycophenolate mofetil and enteric-coated mycophenolate sodium in recipients of kidney-pancreas transplantation. Ann Transplant 2014; 19:76.</a></li><li><a class="nounderline abstract_t">Leroy C, Rigot JM, Leroy M, et al. Immunosuppressive drugs and fertility. Orphanet J Rare Dis 2015; 10:136.</a></li><li><a class="nounderline abstract_t">Montero N, Webster AC, Royuela A, et al. Steroid avoidance or withdrawal for pancreas and pancreas with kidney transplant recipients. Cochrane Database Syst Rev 2014; :CD007669.</a></li><li><a class="nounderline abstract_t">Kaufman DB, Leventhal JR, Koffron AJ, et al. A prospective study of rapid corticosteroid elimination in simultaneous pancreas-kidney transplantation: comparison of two maintenance immunosuppression protocols: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. Transplantation 2002; 73:169.</a></li><li><a class="nounderline abstract_t">Gallon LG, Winoto J, Chhabra D, et al. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. Transplantation 2007; 83:1324.</a></li><li><a class="nounderline abstract_t">Muthusamy AS, Vaidya AC, Sinha S, et al. Alemtuzumab induction and steroid-free maintenance immunosuppression in pancreas transplantation. Am J Transplant 2008; 8:2126.</a></li><li><a class="nounderline abstract_t">Bank JR, Heidt S, Moes DJ, et al. Alemtuzumab Induction and Delayed Acute Rejection in Steroid-Free Simultaneous Pancreas-Kidney Transplant Recipients. Transplant Direct 2017; 3:e124.</a></li><li><a class="nounderline abstract_t">Cerise A, Shaker T, LeNguyen P, et al. Recipient and Graft Outcomes in Simultaneous Kidney and Pancreas Transplantation With Steroid Avoidance in the United States. Transplantation 2023; 107:521.</a></li><li><a class="nounderline abstract_t">Ciancio G, Sageshima J, Chen L, et al. Advantage of rapamycin over mycophenolate mofetil when used with tacrolimus for simultaneous pancreas kidney transplants: randomized, single-center trial at 10 years. Am J Transplant 2012; 12:3363.</a></li><li><a class="nounderline abstract_t">Girman P, Lipár K, Kočík M, et al. Sirolimus vs mycophenolate mofetil (MMF) in primary combined pancreas and kidney transplantation. Results of a long-term prospective randomized study. Am J Transplant 2020; 20:779.</a></li><li><a class="nounderline abstract_t">Cantarovich D, Kervella D, Karam G, et al. Tacrolimus- versus sirolimus-based immunosuppression after simultaneous pancreas and kidney transplantation: 5-year results of a randomized trial. Am J Transplant 2020; 20:1679.</a></li><li><a class="nounderline abstract_t">Stock PG, Mannon RB, Armstrong B, et al. Challenges of calcineurin inhibitor withdrawal following combined pancreas and kidney transplantation: Results of a prospective, randomized clinical trial. Am J Transplant 2020; 20:1668.</a></li></ol></div><div id="topicVersionRevision">Topic 118566 Version 8.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35266622" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : OPTN/SRTR 2020 Annual Data Report: Pancreas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8748413" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The impact of midline versus transverse incisions on wound complications and outcome in simultaneous pancreas-kidney transplants: a retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The Current State of Pancreas Transplantation in the USA—A Registry Report</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15480177" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Ipsilateral placement of simultaneous pancreas and kidney allografts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29952108" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Ipsilateral versus contralateral placement of the pancreas allograft in pancreas after kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22186095" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Pancreas graft thrombosis:  causes, prevention, diagnosis, and intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30525250" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Retrospective study on detection, treatment, and clinical outcome of graft thrombosis following pancreas transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31628880" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Contrast-enhanced ultrasound of the transplant pancreas in the post-operative setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28719059" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Pancreatic allograft thrombosis: Suggestion for a CT grading system and management algorithm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28707821" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Splenic Vein Thrombosis Following Pancreas Transplantation: Identification of Factors That Support Conservative Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31152563" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Susceptibility-directed anticoagulation after pancreas transplantation: A single-center retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16008587" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Pancreas transplant outcomes for United States (US) and non-US cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR) as of June 2004.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24410731" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pancreas transplantation with portal venous drainage with an emphasis on technical aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27358771" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Exocrine drainage in vascularized pancreas transplantation in the new millennium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29683972" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Bladder Versus Enteric Drainage of Exocrine Secretions in Pancreas Transplantation: A Retrospective Analysis of the United Network for Organ Sharing Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28696022" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Outcomes in Pancreas Transplantation With Exocrine Drainage Through a Duodenoduodenostomy Versus Duodenojejunostomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21463823" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A novel technique of portal-endocrine and gastric-exocrine drainage in pancreatic transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28672081" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Concurrent biopsies of both grafts in recipients of simultaneous pancreas and kidney demonstrate high rates of discordance for rejection as well as discordance in type of rejection - a retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17060846" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The long-term management of pancreas transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7794066" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Results of pancreas transplantation with portal venous and enteric drainage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9020324" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Simultaneous pancreas/kidney transplantation--a comparison of enteric and bladder drainage of exocrine pancreatic secretions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9422403" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Long-term pancreas allograft outcome in simultaneous pancreas-kidney transplantation: a comparison of enteric and bladder drainage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16212628" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : An evidence-based analysis of simultaneous pancreas-kidney and pancreas transplantation alone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30838785" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Enteric conversion after bladder-drained pancreas transplantation is not associated with worse allograft survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32548244" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Enteric Conversion of Bladder-drained Pancreas as a Predictor of Outcomes in Almost 600 Recipients at a Single Center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2185105" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Systemic venous drainage of pancreas allografts as independent cause of hyperinsulinemia in type I diabetic recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26172035" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A comparison of long-term outcomes of portal versus systemic venous drainage in pancreatic transplantation: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2645667" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Combined hepatic and pancreaticoduodenal procurement for transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21362047" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Preparation of the pancreas allograft for transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21720668" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : 2011 update on pancreas transplantation: comprehensive trend analysis of 25,000 cases followed up over the course of twenty-four years at the International Pancreas Transplant Registry (IPTR).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29292605" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : OPTN/SRTR 2016 Annual Data Report: Pancreas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26982345" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Pancreas Transplantation of US and Non-US Cases from 2005 to 2014 as Reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29735033" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Pancreas Transplantation for Patients with Type 1 and Type 2 Diabetes Mellitus in the United States: A Registry Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2305459" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Influence of preservation time on outcome and metabolic function of bladder-drained pancreas transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23711225" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : A composite risk model for predicting technical failure in pancreas transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28636074" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Optimizing outcomes in pancreas transplantation: Impact of organ preservation time.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27203593" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Long-term Outcomes for Living Pancreas Donors in the Modern Era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21158928" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Segmental live donor pancreas transplantation: review and critique of rationale, outcomes, and current recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3894793" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Recurrent diabetes mellitus in the pancreas iso- and allograft. A light and electron microscopic and immunohistochemical analysis of four cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22245834" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Laparoscopic robot-assisted pancreas transplantation:  first world experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31250486" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The utility of robotic assisted pancreas transplants - a single center retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9767555" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Randomized comparison of triple therapy and antithymocyte globulin induction treatment after simultaneous pancreas-kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9123463" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Simultaneous use of tacrolimus and mycophenolate mofetil in combined pancreas-kidney transplant recipients: a multi-center report. The FK/MMF Multi-Center Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15114097" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Prospective, randomized trial of the effect of antibody induction in simultaneous pancreas and kidney transplantation: three-year results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20426494" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Immunosuppression in simultaneous pancreas-kidney transplantation: progress to date.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23254700" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Trends in immunosuppression after pancreas transplantation:  what is in the pipeline?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23672537" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Induction therapy in pancreas transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24236648" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Immunosuppression for pancreas transplantation with an emphasis on antibody induction strategies: review and perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22002345" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Thymoglobulin versus basiliximab induction therapy for simultaneous kidney-pancreas transplantation: impact on rejection, graft function, and long-term outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18694474" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : A comparison of alemtuzumab with basiliximab induction in simultaneous pancreas-kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15880067" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Calcineurin inhibitor- and steroid-free immunosuppression in pancreas-kidney and solitary pancreas transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10653379" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Simultaneous kidney-pancreas transplantation without antilymphocyte induction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12814477" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Prospective, randomized, multi-center trial of antibody induction therapy in simultaneous pancreas-kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25645787" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Induction therapy in simultaneous pancreas-kidney transplantation: thymoglobulin versus basiliximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19920781" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25131073" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : 5-year results of a prospective, randomized, single-center study of alemtuzumab compared with rabbit antithymocyte globulin induction in simultaneous kidney-pancreas transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15114089" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in primary simultaneous pancreas-kidney transplantation: 1-year results of a large multicenter trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15814547" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Efficacy and safety of tacrolimus compared with cyclosporin microemulsion in primary SPK transplantation: 3-year results of the Euro-SPK 001 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15194369" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Single-center, open, prospective, randomized pilot study comparing cyclosporine versus tacrolimus in simultaneous pancreas-kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8600635" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10075592" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Long-term results of pancreas transplantation under tacrolius immunosuppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29266398" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Randomized open-label crossover assessment of Prograf vs Advagraf on immunosuppressant pharmacokinetics and pharmacodynamics in simultaneous pancreas-kidney patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15239622" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Glucose metabolism after pancreas transplantation: cyclosporine versus tacrolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20055797" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Incidence of and risk factors for posttransplant diabetes mellitus after pancreas transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9422404" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Mycophenolate mofetil decreases rejection in simultaneous pancreas-kidney transplantation when combined with tacrolimus or cyclosporine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10919583" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Randomized, prospective trial of mycophenolate mofetil versus azathioprine for prevention of acute renal allograft rejection after simultaneous kidney-pancreas transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9884272" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : A study comparing mycophenolate mofetil to azathioprine in simultaneous pancreas-kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9721799" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Mycophenolate mofetil in pancreas transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29791046" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Impact of intensive dosing of mycophenolate on pancreas allograft survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16452491" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18091520" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Improvement in 3-month patient-reported gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16699457" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24509827" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Comparison of the exposure of mycophenolate mofetil and enteric-coated mycophenolate sodium in recipients of kidney-pancreas transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26490561" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Immunosuppressive drugs and fertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25220222" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Steroid avoidance or withdrawal for pancreas and pancreas with kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11821726" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : A prospective study of rapid corticosteroid elimination in simultaneous pancreas-kidney transplantation: comparison of two maintenance immunosuppression protocols: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17519781" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18828772" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Alemtuzumab induction and steroid-free maintenance immunosuppression in pancreas transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28349124" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Alemtuzumab Induction and Delayed Acute Rejection in Steroid-Free Simultaneous Pancreas-Kidney Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36195029" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Recipient and Graft Outcomes in Simultaneous Kidney and Pancreas Transplantation With Steroid Avoidance in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22946986" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Advantage of rapamycin over mycophenolate mofetil when used with tacrolimus for simultaneous pancreas kidney transplants: randomized, single-center trial at 10 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31561278" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Sirolimus vs mycophenolate mofetil (MMF) in primary combined pancreas and kidney transplantation. Results of a long-term prospective randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32022990" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Tacrolimus- versus sirolimus-based immunosuppression after simultaneous pancreas and kidney transplantation: 5-year results of a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32039559" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Challenges of calcineurin inhibitor withdrawal following combined pancreas and kidney transplantation: Results of a prospective, randomized clinical trial.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
